Medical News / Coverage ASRS 2019: Vrinda Hershberger, MD, PhD: Faricimab for Diabetic Macular Edema

An analysis of the phase 2 BOULEVARD trial presented at the 2019 American Society of Retina SpecialistsAnnual Meeting highlighted the anatomical benefits and the potential for extended durability with faricimab compared with anti-VEGF mono therapy in patients with diabetic macular edema (DME). 

 Data from the analyses, which was presented for the first time at ESRS 2019 by Vrinda Hershberger, MD, PhD, found that faricimab not only led to improved best-corrected visual acuity and central subfield thickness from baseline, but also provided anatomical benefits and displayed a potential for extended durability compared to anti-VEGF monotherapy. 

 In between sessions, Hershberger, vitreal retina surgeon with Florida Eye Associates, sat down with MD Magazine at ESRS 2019 to discuss the findings of the analysis and what they mean going forward. 

 Source: MDmag By reading more or clicking on the link below, you are leaving this site and going to another site run by another organization ...

read more

With fixed incomes a reality for many elderly patients, finding less expensive alternatives to current therapies ... read more
Despite not being a physician, Lawrence Hoffheimer, a former healthcare attorney who practice in Washington D.C. ... read more
Heading into the 2019 American Society of Retina Specialists Annual Meeting, sessions and studies pertaining to ... read more
Results of a new study show that receiving same day intravitreal anti-VEGF treatments was highly preferred ... read more